Intracellular calcium and hormone release from nerve endings of the neurohypophysis in the presence of opioid agonists and antagonists.
Rat neural lobes and isolated nerve terminals from the neurohypophysis were stimulated in the presence of different opioid agonists and antagonists. The secretion of arginine vasopressin and oxytocin and rise in cytoplasmic calcium induced by depolarization were analyzed by radioimmunoassay and the fluorescent probe fura-2, respectively. The kappa-agonists dynorphin A(1-13) and dynorphin A(1-8) did not affect electrically evoked release of vasopressin, although oxytocin release was slightly reduced. U-50 488, a relatively specific kappa-receptor agonist, had no effect on the amount of vasopressin or oxytocin secreted, although it significantly reduced K(+)-evoked changes in [Ca2+]i in isolated nerve endings. Two kappa-receptor antagonists, MR 2266 and diprenorphin, alone had no effect on vasopressin and oxytocin secretion from isolated nerve endings depolarized with potassium. Opioid agonists less selective for the kappa receptors, etorphin and ethylketocyclazocin, were found to inhibit the release of both vasopressin and oxytocin significantly. Naloxone, a nonselective opiate receptor antagonist, alone had no effect on vasopressin release but potentiated the electrically evoked release of oxytocin. Naloxone also could overcome the inhibitory effect of etorphin on oxytocin and vasopressin release observed after electrical stimulation of the neural lobe. A number of inconsistencies therefore exist between the effects of opioid agonists and antagonists on neuropeptide release and on the evoked changes in [Ca2+]i. In view of these inconsistencies and the high concentrations of opioid agonists and antagonists necessary to modify release, we conclude that it is doubtful that opioid molecules have a physiological role in controlling neurohypophysial secretion.
Centre de Neurochimie, Strasbourg, France.
G
G
Dayanithi
E L
EL
Stuenkel
J J
JJ
Nordmann
D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism*; D001575:Benzomorphans / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D003593:Cytoplasm / Q000378:metabolism; D004174:Diprenorphine / Q000494:pharmacology*; D004399:Dynorphins / Q000494:pharmacology*; D004558:Electric Stimulation; D066298:In Vitro Techniques; D008297:Male; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D009294:Narcotics / Q000494:pharmacology*; D009411:Nerve Endings / Q000187:drug effects* / Q000502:physiology; D010121:Oxytocin / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology*; D010904:Pituitary Gland, Posterior / Q000187:drug effects* / Q000502:physiology; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar
D001575:Benzomorphans; D009292:Narcotic Antagonists; D009294:Narcotics; D010446:Peptide Fragments; D001127:Arginine Vasopressin; D004174:Diprenorphine; D009270:Naloxone; D010121:Oxytocin; C027247:MR 2266; C026843:dynorphin (1-13); D004399:Dynorphins; C026770:dynorphin (1-8); D011188:Potassium; D002118:Calcium